Introduction: The Biomarkers Used for HCC Surveillance Ultrasound (US) is the backbone of hepatocellular carcinoma (HCC) surveillance, but its sensitivity for early-stage HCC is imperfect. Blood-based biomarkers are attractive adjuncts because they are easy to repeat and potentially detect tumors missed by US.
Introduction: The Biomarkers Used for HCC Surveillance
Ultrasound (US) is the backbone of hepatocellular carcinoma (HCC) surveillance, but its sensitivity for early-stage HCC is imperfect. Blood-based biomarkers are attractive adjuncts because they are easy to repeat and potentially detect tumors missed by US. The commonly studied serum biomarkers include:
AFP (alpha-fetoprotein): classic HCC marker, but limited specificity in active liver inflammation.
AFP-L3: lectin-reactive AFP fraction, thought to reflect more malignant AFP isoforms.
DCP (des-gamma-carboxy prothrombin/PIVKA-II): associated with HCC biology and vascular invasion in some cohorts.
This trial tested whether combining these biomarkers with US improves early-stage detection.
Summary
In this randomized controlled trial, 1208 high-risk adults (cirrhosis or high-risk HBV) were assigned to biannual surveillance with US alone or US plus serum biomarkers (AFP, AFP-L3, DCP). Biomarker thresholds triggering diagnostic imaging were AFP >100 ng/mL, AFP-L3 >10%, or DCP >2 ng/mL. Over follow-up, 35 HCCs occurred in the US-only arm and 27 in the combined arm, with no difference in early-stage HCC detection between strategies (HR 0.81; P=.45). Late-stage cancers were similar in both groups. Within the biomarker arm, AFP-L3 alone performed similarly to using all three biomarkers combined. Overall, adding AFP/AFP-L3/DCP to ultrasound did not improve early HCC detection in this study, and the trial was not powered to prove benefit for biomarkers beyond US ± AFP.
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the fastest-growing cause of hepatocellular carcinoma (HCC). Because a substantial proportion of MASLD-related HCC develops before cirrhosis, better tools are needed to identify high-risk patients who...
Introduction: The HIMALAYA trial established durvalumab plus tremelimumab (STRIDE) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). However, many real-world patients do not meet the strict eligibility criteria of clinical trials. This multicenter study...
Introduction: Prognosis in unresectable hepatocellular carcinoma (HCC) depends not only on tumor burden but also on liver function and nutritional status. This study evaluated the prognostic value of ALBI grade, EZ-ALBI grade, and sarcopenia in...
Introduction: Hepatocellular carcinoma (HCC) surveillance enables earlier diagnosis and improves survival. This largest UK multicenter study evaluated how patients are diagnosed in routine clinical practice and identified major gaps in the surveillance pathway. Why was...
Introduction: Selective internal radiation therapy (SIRT) using yttrium-90 (Y90) glass microspheres is an established locoregional treatment for hepatocellular carcinoma (HCC), but guideline recommendations remain inconsistent. This large prospective multicenter study evaluated the real-world effectiveness, safety,...
Introduction: Atezolizumab–bevacizumab (A/B) and durvalumab–tremelimumab (STRIDE) are preferred first-line treatments for advanced hepatocellular carcinoma (HCC). Because bevacizumab inhibits VEGF, concerns remain regarding bleeding and thromboembolic complications in patients with underlying cirrhosis and portal hypertension. Why...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.